ArticleNational science review2026
A transistor-based point-of-care assay with lipid-capped sensory interface for clinical profiling of cardiovascular diseases.
Article in National science review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lipid-capped transistors bring cardiac testing closer to the bedside.National science review · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Point-of-care (POC) testing for electrical detection of cardiovascular disease (CVD) can enable effective screening and surveillance. However, the complexity and diversity of serum samples interfere with the transduction of electrical signals, limiting the sensitivity and accuracy of the biochemical assay. Here, we present the development and performance of an electrical POC assay based on self-assembled lipid-capped transistor sensory interfaces for the simultaneous detection and profiling of five myocardial injury biomarkers, with detection limits as low as pg/mL levels. By reducing Debye screening and non-specific adsorption through phospholipid self-assembly, the electrical assay maintains high sensitivity and specificity in human serum, as well as promising quantitative accuracy. For acute myocardial infarction (AMI) animal modeling, our assay detects variations in key biomarker characteristics within 15 to 45 min after the onset of myocardial injury, with a detection time window more than 30 min earlier than biochemical assays. Through the combination profiling of five biomarker signatures from 265 clinical serum samples, our assay achieves 91.7% accuracy for AMI identification and 79.6% accuracy for cardiovascular disease classification, effectively monitoring the prognosis of AMI patients. This assay may provide reliable clinical guidance for the early diagnosis, risk assessment, and prognosis monitoring of CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.